PropertyValue
?:abstract
  • Coronavirus disease 19 (COVID-19) has posed serious threats to the general population. To relieve the crisis, a comparison of drug effects against COVID-19 is instructive. Between January 27, 2020 and March 21, 2020, a total of 333 patients treated with arbidol, corticosteroids, hydroxychloroquine, lopinavir/ritonavir, or oseltamivir monotherapy, having definite outcomes and serological antibody detection results, were retrospectively analyzed. The hydroxychloroquine group had a significantly reduced duration of hospital stay than the arbidol and corticosteroids groups. The oseltamivir group had a significantly shorter length of hospital stay than the arbidol, corticosteroids, and lopinavir/ritonavir groups. The hydroxychloroquine group had a significantly higher IgM titer than the other four groups and exhibited significantly higher IgG levels than the arbidol, lopinavir/ritonavir, and oseltamivir groups. Our findings indicated that hydroxychloroquine might have the potential for efficient COVID-19 management, while oseltamivir should be prudently considered in combination therapy.
is ?:annotates of
?:creator
?:doi
  • 10.1016/j.virusres.2020.198262
?:doi
?:journal
  • Virus_Res
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/3ad48e454b98221e566ca98424608a66a5bbf139.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7833729.xml.json
?:pmcid
?:pmid
?:pmid
  • 33333102.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Elsevier; Medline; PMC
?:title
  • A retrospective comparison of drugs against COVID-19
?:type
?:year
  • 2020-12-14

Metadata

Anon_0  
expand all